********** Between 1938 and 1971 ...

**********

Between 1938 and 1971 as many as 4 million women in the United States took diethylstilbestrol (DES) an oral synthetic nonsteroidal estrogen for the intention of improving pregnancy outcomes. (12) In 1953 it was demonstrated that DE did not obstruct miscarriage and other pregnancy complications. However, physicians continued to prescribe DE to pregnant women until at least 1971 when a connection was established between in utero DE outlook and the development of clear lonely dwelling adenocarcinoma of the vagina and cervix in the daughters of women who had taken DE during pregnancy. (3) In 1971 the U pabulum and Drug Administration issued a warning against the use of DE in pregnant women (4) DE continued to be used in various European countries until the early 1980s

The association between in utero DE frontage and vaginal clear cell adenocarcinoma has been well documented. Other adverse associations have been identified in DES-expos women and their offspring, and animal studies have shown consequences in the next generation (grandchildren). (56) The Center for Disease command and Prevention has instituted a campaign to educate health care professionals and patients about the risks associated with frontage to this synthetic estrogen.

It is difficult to determine the number of parts with DES exposure. However, physicians should be alert for patients who may have been expos to this agent and should be aware of the possible deductions of such exposure. Dosages of DE varied greatly, as did the time during pregnancy that DE was taken. These factors may contribute to the wide range of adverse consequences in the offspring of women who took DE while they were pregnant.

Illustrative Case

A 37-year-old woman who had been trying to conceive for brace years came to her physician's office to discuss fertility issues. Her basal material substance temperature charts illustrated presumed ovulatory periods and her husband had a normal sperm analysis. She had an abnormal Papanicolaou (Pap) smear 15 years previously, nevertheless all subsequent Pap smears had been normal. However, her previous physician had noted that her cervix "look funny" The patient was the oldest of four siblings; her mother had brace miscarriages before the patient was born.

The patient's general physical examination was normal. forward pelvic examination, her vagina was normal, unless her cervix had a pseudopolyp. Because of the patient's history of infertility and the consideration that she might have been expos to DE in utero hysterosalpingography was ordered, and the patient was asked to discuss the possibility of DE aspect with her mother.

The patient's mother accompanied her to the follow-up visit. The hysterosalpingogram showed that the patient had a T-shaped uterus. Her mother vaguely remembered taking medication to impede another miscarriage when she was pregnant with her daughter.

after to a follow-up visit, the patient's mother contacted her physician for a duplicate of her obstetric records. The patient was referr to a reproductive endocrinologist for evaluation of infertility.

Identifying DE Exposure

It is important to include questions about DE in the routine medical history of women who gave birth between 1938 and 1971 and of patients who were born during those years (37) (Table 1) (2) In parts born outside the United States, there is a chance of DE front if they gave birth or were born as late as the 1980 Many women may not be aware that they received DE during pregnancy, in part because the synthetic estrogen was marketed below many different names. (2,8)

single recent study (9) found that an office body intervention was successful in increasing awareness of DE in all senses among clinical staff. The intervention entailed the addition of questions about DE outlook to the routine health history form.

Women Who Took DE During Pregnancy

Women who took DE while they were pregnant have a slightly higher incidence of breast cancer compared with the general population. The relative risk ranges from 127 to 135 in several studies. (10) In comparison, the relative risk of breast cancer is 13 in women who have taken hormone therapy for more than five years,11 and 21 in women with a family history of breast cancer. (12) Women who were prescribed DE during pregnancy should have annual mammography and clinical breast examinations after the age of 50 (12) [Strength of recommendation (SOR) A, evidence-based guideline]

No increased risk of other hormone-dependent cancers has been rest in women with DES exposing during pregnancy. Therefore, other preventive and screening measures should be based upon standard guidelines.

Daughters with in Utero DE Exposure

In the daughters of women who took DE during pregnancy, the incidence of clear small cavity adenocarcinoma of the vagina and cervix ranges from 14 cases by 1,000 exposed persons to undivided case per 10,000 exposed [i]role[/i]s (13) Clear cell adenocarcinoma is principally likely to develop when women with in utero DE outlook are between 17 and 22 years of age. However, cases have been diagnosed in women in their 30 and 40 and there is affair about a possible second age-incidence peak of clear confined apartment adenocarcinoma as women with in utero DE frontage grow older. (14) Clear lonely dwelling adenocarcinoma of the vagina and cervix is rare in women without in utero DE exposure; in of the like kind cases, the cancer usually make knowns in the postmenopausal period. (15)